Criticism mounts of India's 'abrupt' approval of local vaccine

Published January 6, 2021
A volunteer is seen during a dry run or a mock drill for the Covid-19 coronavirus vaccine, at a private hospital in Allahabad on January 5. — AFP
A volunteer is seen during a dry run or a mock drill for the Covid-19 coronavirus vaccine, at a private hospital in Allahabad on January 5. — AFP

Criticism of India's approval of a local Covid-19 vaccine without proof of its efficacy grew on Wednesday after news that a regulatory panel approved the shot just one day after asking the vaccine maker for more evidence it would work.

The recommendations of the Indian drug regulator's Subject Expert Committee (SEC) released on Tuesday show that the panel asked Bharat Biotech International Ltd to present more efficacy data for its Covid-19 shot before it could consider approving the treatment.

“After detailed deliberation, the committee recommended that the firm [...] may perform interim efficacy analysis for further consideration of restricted emergency use approval,” the SEC's recommendations in a Jan 1 meeting show.

The very next day, the committee recommended approving Bharat Biotech's vaccine for “restricted use in [an] emergency situation in public interest as an abundant precaution”.

The SEC also separately recommended emergency use authorisation for the Oxford University/AstraZeneca Covid-19 vaccine, being produced by India's Serum Institute.

The greenlighting of Bharat Biotech's Covaxin had already faced criticism from opposition lawmakers and health experts for lack of efficacy data, typically obtained from a large, Phase III human trial — which the manufacturer is still conducting.

News of the SEC's recommendations spurred further criticism.

“Was the Subject Expert Committee's (SEC) approval a command performance? This is as serious as it can get,” Manish Tewari, an opposition lawmaker, said on Twitter.

Health experts questioned why the SEC abruptly recommended approval one day after asking Bharat Biotech for more analysis.

“The SEC [...] appears to have been pressured overnight into reconsidering its decision and giving approval the next day, albeit hedged in by many conditions,” the All India People's Science Network, a network of science advocacy groups, said in a statement.

“We are perplexed at the abrupt change in thinking of the SEC from the first two meetings to the third day on which the approval was recommended while apparently discounting the need for efficacy data as the condition of the approval,” the All India Drug Action Network, a non-profit health watchdog, said.

Both Bharat Biotech and government officials have pointed to regulatory provisions that allow for quick drug approval for serious diseases even without Phase III trial data.

Neither India's drugs regulator nor Bharat Biotech responded to Reuters requests for comment on Wednesday.

Regulators also granted approval to Bharat Biotech's vaccine only “in clinical trial mode”, unusually cryptic language that left some experts baffled.

“They've introduced terminologies that are confusing,” said Giridhar Babu, a professor of epidemiology at the Public Health Foundation of India.

“The phrase 'in clinical trial mode' is not generally a term you will see in approvals.”

Any confusion around vaccines could harm immunisation programmes by causing distrust, Babu said. “It takes decades of work to build confidence in vaccines.”



State Bank’s bluff
Updated 28 Jan 2021

State Bank’s bluff

Banks are sceptical of the State Bank’s ‘forward guidance’ if their bidding behaviour in govt debt auctions is anything to go by.
Unburied conscience
Updated 28 Jan 2021

Unburied conscience

Certain events in a nation’s history (however traumatic) need to be retrieved from the cupboard of memory.
A jab in time
27 Jan 2021

A jab in time

Vaccines are evidently not an instant panacea.


28 Jan 2021

Streamlining madressahs

SUCCESSIVE governments over the decades have grappled with the challenge of regulating the tens of thousands of...
Updated 28 Jan 2021

Farmers’ protest

It is possible that an unyielding Modi has painted himself into a corner in a politically crucial election year.
28 Jan 2021

A broader investigation

THE Broadsheet controversy may be poised to open up a Pandora’s Box. Reportedly, the government is planning to...
Updated 27 Jan 2021

Pemra’s powers

The right to freedom of expression has been curtailed to such an extent that it invites comparisons with martial law times.
27 Jan 2021

Increasing debt

THE numbers released by the State Bank regarding the government’s domestic debt stock and servicing at the end of...
27 Jan 2021

Women in conflict

“WHEN the guns fall silent, it does not mean the suffering of women and girls stops. The suffering and abuse that...